Gerresheimer AGGRRMF 67 ROE % is -3.63% as of Aug. 2025. GuruFocus rates GRRMF with a GF Score™ of 67/100 and a GF Value™ of $119.57 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Gerresheimer AG ranks worse than 52.44% on this metric.
The historical rank and industry rank for Gerresheimer AG's ROE % or its related term are showing as below:
GRRMF'
s ROE % Range Over the Past 10 Years
Min: 1.6 Med: 9.39 Max: 17.99
Current: 1.6
During the past 13 years, Gerresheimer AG's highest ROE % was 17.99%. The lowest was 1.60%. And the median was 9.39%.
GRRMF's ROE % is ranked worse than 52.44% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs GRRMF: 1.60
Gerresheimer AG (OTCPK:GRRMF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Aug. 2025) net income data. The Revenue data used here is four times the quarterly (Aug. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Gerresheimer AG ROE % Related Terms
Gerresheimer AG ROE % Historical Data
* Premium members only.
The historical data trend for Gerresheimer AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Gerresheimer AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gerresheimer AG ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gerresheimer AG's ROE % distribution charts can be found below:
* The bar in red indicates where Gerresheimer AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Aug. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Gerresheimer AG (GRRMF) has a ROE % of -3.63% as of Aug. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Gerresheimer AG and its competitors. Over the past decade, Gerresheimer AG's ROE % has ranged from 1.60 to 17.99. According to the industry distribution chart, Gerresheimer AG ranks #419 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 52.4%.
Is Gerresheimer AG's ROE % too high?
Gerresheimer AG's current ROE % is -3.63%. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 17.99. Based on the distribution chart, Gerresheimer AG ranks #419 out of 799 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gerresheimer AG has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gerresheimer AG's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gerresheimer AG ranks #419 out of 799 companies for ROE %. This places Gerresheimer AG in the lower half of its industry. The industry median ROE % is 2.42. Historically, Gerresheimer AG's own ROE % has ranged from 1.60 to 17.99 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Gerresheimer AG and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gerresheimer AG's current ROE % is -3.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gerresheimer AG stock overvalued right now?
Based on GuruFocus' analysis, Gerresheimer AG (GRRMF) is currently considered Possible Value Trap. The stock's GF Value™ is $119.57, compared to a current price of $32.10 — trading 73.2% below its estimated fair value. The current ROE % is -3.63%. Gerresheimer AG's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Gerresheimer AG (GRRMF), the current ROE % is -3.63% as of Aug. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gerresheimer AG (GRRMF) Overvalued in 2026?
Based on GuruFocus' analysis, Gerresheimer AG stock appears to be undervalued.
The current stock price of $32.10 is trading 73.2% below its estimated GF Value™ of $119.57.
GuruFocus considers Gerresheimer AG to be Possible Value Trap.
Key valuation signals for GRRMF:
ROE %: -3.63%
GF Value™: $119.57 vs. price of $32.10 (73.2% below fair value)
No single metric tells the full story. See the GRRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
67GF Score
Get the complete analysis for GRRMF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRRMF has been successfully added to your 
